ArticleAmerican journal of hypertension2025
A Comparative Study of the Clinical Efficacy of Superselective Adrenal Artery Embolization for Patients with Primary Aldosteronism.
Article in American journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Primary aldosteronism: pharmacotherapyFrontiers in endocrinology · 2025Pooled it
- Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism.Journal of the American Heart Association · 2026Article
- Beyond Drugs and Surgery: Superselective Adrenal Artery Embolization Redefines Primary Aldosteronism Management-A Systematic Review and Meta-Analysis.International journal of endocrinology · 2026Article
- Review
- Recent Advances in Adrenal Ablation for Primary Aldosteronism.American journal of hypertension · 2025Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
Abstract
backgroundSuperselective adrenal artery embolization (SAAE) is a potential treatment option for patients with primary aldosteronism (PA).
methodsThis retrospective study aimed to compare the clinical efficacy and impact on cardiorenal organs of SAAE with mineralocorticoid receptor antagonists (MRA) and adrenalectomy (ADX) in patients with PA. After a median follow-up of 19 (12.5-26.5) months, 148 patients with PA were included in the study. The study cohorts consisted of 58, 53, and 37 patients treated with SAAE, MRA, and ADX, respectively.
resultsDuring follow-up, SAAE achieved a significantly greater level of complete clinical success in the treatment of PA compared to MRA (P < 0.05). Within the SAAE group (n = 58), 19 (32.8%) and 26 (44.8%) patients achieved complete and partial clinical success, respectively. However, there were no significant differences in the prognostic parameters of the cardiorenal organs between the two groups. In the comparison of patients with UPA treated with SAAE (n = 35) and ADX (n = 37), there was no significant difference in clinical efficacy between the two groups.
conclusionsThe findings of this study suggest that for patients with PA who are not suitable for ADX, SAAE is a viable treatment option that significantly improves clinical outcomes compared to MRA treatment.
Indexed as
Identifiers
40372076What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.